Deutsche Bank assumed coverage on shares of CVS Health (NYSE:CVS) in a report released on Thursday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $91.00 price objective on the pharmacy operator’s stock.

Several other research firms have also weighed in on CVS. Morgan Stanley reaffirmed a buy rating and issued a $74.00 price objective on shares of CVS Health in a research note on Sunday, August 11th. ValuEngine lowered CVS Health from a sell rating to a strong sell rating in a research note on Tuesday, July 2nd. Standpoint Research raised CVS Health from a hold rating to a buy rating in a research note on Wednesday, June 5th. Cowen reaffirmed an outperform rating and issued a $76.00 price objective (up from $69.00) on shares of CVS Health in a research note on Tuesday, August 27th. Finally, Citigroup raised their price objective on CVS Health from $68.00 to $72.00 and gave the company a buy rating in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. CVS Health presently has a consensus rating of Buy and an average target price of $75.91.

NYSE:CVS opened at $64.06 on Thursday. The stock’s 50-day simple moving average is $59.42 and its 200 day simple moving average is $55.86. The firm has a market capitalization of $83.10 billion, a PE ratio of 9.05, a price-to-earnings-growth ratio of 1.40 and a beta of 0.85. The company has a quick ratio of 0.64, a current ratio of 0.95 and a debt-to-equity ratio of 1.39. CVS Health has a twelve month low of $51.72 and a twelve month high of $82.15.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, August 7th. The pharmacy operator reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.19. The business had revenue of $63.43 billion for the quarter, compared to analyst estimates of $62.66 billion. CVS Health had a return on equity of 16.15% and a net margin of 1.91%. CVS Health’s revenue was up 35.2% compared to the same quarter last year. During the same period last year, the firm posted $1.69 earnings per share. On average, analysts anticipate that CVS Health will post 6.96 EPS for the current fiscal year.

In other news, CFO Eva C. Boratto sold 8,130 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $65.00, for a total transaction of $528,450.00. Following the completion of the transaction, the chief financial officer now directly owns 55,273 shares in the company, valued at $3,592,745. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.53% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently modified their holdings of CVS. Nuveen Asset Management LLC raised its position in shares of CVS Health by 16,194.7% during the second quarter. Nuveen Asset Management LLC now owns 12,112,044 shares of the pharmacy operator’s stock worth $659,986,000 after acquiring an additional 12,037,713 shares during the last quarter. Geode Capital Management LLC increased its holdings in CVS Health by 36.2% in the fourth quarter. Geode Capital Management LLC now owns 16,462,292 shares of the pharmacy operator’s stock worth $1,076,697,000 after purchasing an additional 4,376,604 shares in the last quarter. Ellis Investment Partners LLC increased its holdings in CVS Health by 5,752.4% in the first quarter. Ellis Investment Partners LLC now owns 1,858,328 shares of the pharmacy operator’s stock worth $1,858,000 after purchasing an additional 1,826,575 shares in the last quarter. Morgan Stanley increased its holdings in CVS Health by 12.8% in the second quarter. Morgan Stanley now owns 13,765,635 shares of the pharmacy operator’s stock worth $750,088,000 after purchasing an additional 1,560,142 shares in the last quarter. Finally, Prudential PLC increased its holdings in CVS Health by 54.8% in the second quarter. Prudential PLC now owns 3,737,874 shares of the pharmacy operator’s stock worth $203,137,000 after purchasing an additional 1,323,366 shares in the last quarter. Institutional investors own 75.89% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Recommended Story: What Factors Can Affect Return on Equity?

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.